Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1233069.RAZU-w-Sa040ULAzEdftQQwqkkkomR1LcaHIXK2V5dHd4130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1233069.RAZU-w-Sa040ULAzEdftQQwqkkkomR1LcaHIXK2V5dHd4130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1233069.RAZU-w-Sa040ULAzEdftQQwqkkkomR1LcaHIXK2V5dHd4130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1233069.RAZU-w-Sa040ULAzEdftQQwqkkkomR1LcaHIXK2V5dHd4130_provenance.
- NP1233069.RAZU-w-Sa040ULAzEdftQQwqkkkomR1LcaHIXK2V5dHd4130_assertion description "[Alectinib/CH5424802 is a known inhibitor of anaplastic lymphoma kinase (ALK) and is being evaluated in clinical trials for the treatment of ALK fusion-positive non-small cell lung cancer (NSCLC).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1233069.RAZU-w-Sa040ULAzEdftQQwqkkkomR1LcaHIXK2V5dHd4130_provenance.
- NP1233069.RAZU-w-Sa040ULAzEdftQQwqkkkomR1LcaHIXK2V5dHd4130_assertion evidence source_evidence_literature NP1233069.RAZU-w-Sa040ULAzEdftQQwqkkkomR1LcaHIXK2V5dHd4130_provenance.
- NP1233069.RAZU-w-Sa040ULAzEdftQQwqkkkomR1LcaHIXK2V5dHd4130_assertion SIO_000772 25349307 NP1233069.RAZU-w-Sa040ULAzEdftQQwqkkkomR1LcaHIXK2V5dHd4130_provenance.
- NP1233069.RAZU-w-Sa040ULAzEdftQQwqkkkomR1LcaHIXK2V5dHd4130_assertion wasDerivedFrom befree-2016 NP1233069.RAZU-w-Sa040ULAzEdftQQwqkkkomR1LcaHIXK2V5dHd4130_provenance.
- NP1233069.RAZU-w-Sa040ULAzEdftQQwqkkkomR1LcaHIXK2V5dHd4130_assertion wasGeneratedBy ECO_0000203 NP1233069.RAZU-w-Sa040ULAzEdftQQwqkkkomR1LcaHIXK2V5dHd4130_provenance.
- befree-2016 importedOn "2016-02-19" NP1233069.RAZU-w-Sa040ULAzEdftQQwqkkkomR1LcaHIXK2V5dHd4130_provenance.